Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor

Details for Australian Patent Application No. 2004253889 (hide)

Owner Merck & Co., Inc.

Inventors Lee, Ivan; Chen, Alex Minhua; Hansen, Karl; Vydra, Vicky K.; Wenslow, Robert M. Jr.; Ferlita, Russell R.; Cypes, Stephen Howard

Agent Spruson & Ferguson

Pub. Number AU-B-2004253889

PCT Pub. Number WO2005/003135

Priority 60/482,161 24.06.03 US

Filing date 18 June 2004

Wipo publication date 13 January 2005

Acceptance publication date 24 April 2008

International Classifications

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

5 January 2006 PCT application entered the National Phase

  PCT publication WO2005/003135 Priority application(s): WO2005/003135

24 April 2008 Application Accepted

  Published as AU-B-2004253889

21 August 2008 Standard Patent Sealed

21 January 2010 Amendment Made

  The nature of the amendment is: Amend patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

4 October 2012 Alteration of Name

  The name of the patentee has been altered to Merck Sharp & Dohme Corp. Amendments

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253891-Novel additive composition that reduces soot and/or emissions from engines

2004253888-Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases